Mirum Pharmaceuticals (MIRM) Projected to Post Earnings on Wednesday

Mirum Pharmaceuticals (NASDAQ:MIRM) will likely be releasing its earnings data after the market closes on Wednesday, February 26th. Analysts expect Mirum Pharmaceuticals to post earnings of ($0.27) per share and revenue of $96.64 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Mirum Pharmaceuticals Trading Down 1.2 %

Shares of MIRM stock opened at $52.50 on Monday. The company’s 50-day moving average price is $46.21 and its 200-day moving average price is $43.13. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of -25.99 and a beta of 0.96. Mirum Pharmaceuticals has a twelve month low of $23.14 and a twelve month high of $54.23.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, Citigroup raised their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $57.10.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 750 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $32,115.00. Following the sale, the senior vice president now owns 2,926 shares of the company’s stock, valued at approximately $125,291.32. This trade represents a 20.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Peetz sold 9,102 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $438,898.44. Following the sale, the chief executive officer now directly owns 115,920 shares in the company, valued at approximately $5,589,662.40. The trade was a 7.28 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,915 shares of company stock valued at $1,897,920. 22.87% of the stock is owned by corporate insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.